

JUL 16 2004

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/006,394
				Filing Date	June 21, 2002
				First Named Inventor	Li et al.
				Group Art Unit	1646
				Examiner Name	Brannock, M.
Sheet	1	of	2	Attorney Docket Number	PF187D1C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
W	AA	5,155,218	10-13-1992	Weinshank et al.	
X	AB	5,942,414	08-24-1999	Li et al.	
✓	AC	US09/912,292	NOT PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOs: 16401 and 21801

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
W	AD	WO	94/21660		Merck & Co., Inc.	09-29-1994	
	AE	WO	94/05695		New York University	03-17-1994	
	AF	WO	93/07294		NIH	04-15-1993	
	AG	WO	93/12134		Harvard College	06-24-1993	
	AH	WO	92/01810		BRL Screening, Inc.	02-06-1992	
	AI	EP	0590721	A1	Enichem, S.P.A.	04-06-1994	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	AJ	GENBANK Accession No. R17870, "yg10d01.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:31997 5' similar to SP:B2AR_MESAU P04274 BETA-2 ADRENERGIC ;, MRNA sequence," (April 1995).		
	AK	GENBANK Accession No. P04274, "Beta-2 adrenergic receptor (Beta-2 adrenoceptor) (Beta-2 adrenoreceptor)," (March 1995).		
	AL	GENBANK Accession No. R43119, (May 1995).		
	AM	EVA, C. et al., "Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family," FEBS Letters 271:81-4 (1990).		
	AN	FARGIN, A. et al., "The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor," Nature 335:358-60 (1988).		

Examiner Signature		Date Considered	9/20/04
-----------------------	--	--------------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/006,394
				Filing Date	June 21, 2002
				First Named Inventor	Li et al.
				Group Art Unit	1646
				Examiner Name	Brannock, M.
Sheet	2	of	2	Attorney Docket Number	PF187D1C1

**OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WY	AO	FRASER, C.M. et al., "Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation," J. Biol. Chem. 264:11754-11761 (1989).	
	AP	HLA, T. et al., "An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors," J. Biol. Chem. 265(16):9308-13 (1990).	
	AQ	KOBILKA, B.K. et al., "cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor," Proc. Natl. Acad. Sci. 84 :46-50 (1987).	
	AR	KOBILKA, B.K. et al., "Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor," Science 238:650-6 (1987).	
	AS	LEE et al., Drug News and Perspectives 6(7):488-97 (1993).	
	AT	LIBERT, F. et al., "Selective amplification and cloning of four new members of the G protein-coupled receptor family," Science 244:569-72 (1989).	
	AU	MEYERHOF, W. et al., "Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis," FEBS Letters 284(2):155-60 (1991).	
	AV	O'DOWD, B.F. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes," Gene 187:75-81 (1997).	
	AW	OLIVEIRA et al., J. Computer-Aided Molecular Design 7:649-58 (1993).	
	AX	PEPPERL, D.J. et al., CRC Press, 45-6 (1994).	
	AY	ROSS, P.C. et al., "RTA, a candidate G protein-coupled receptor: cloning, sequencing, and tissue distribution," Proc. Natl. Acad. Sci. 87:3052-6 (1990).	
	AZ	SAMBROOK et al., "Molecular Cloning: A Laboratory Manual," Cold Spring Press (1989).	
V	BA	YOSHIMATSU T. et al., "Control of gene expression by artificial introns in Saccharomyces cerevisiae," Science 244:1346-8 (1988).	

Examiner Signature		Date Considered	9/20/04
--------------------	---	-----------------	---------

<sup>1</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.